In May 18th, Zhang Guohua, Secretary of the municipal Party committee, made a thorough investigation of scientific and technological innovation in enterprises and universities. Jiangsu Wanbang biochemical pharmaceutical Limited by Share Ltd, he encouraged the enterprise collaborative innovation research institutes and universities, in-depth, to further strengthen the core technology research and development, strengthen the integrated innovation, and constantly develop new products, as long as deep bio pharmaceutical industry chain.
In May 28th, the reporter walked into Jiangsu Wanbang biochemical pharmaceutical Limited by Share Ltd (hereinafter referred to as Wanbang medicine), visit the enterprises in the industrial technology innovation, innovation platform construction, talent development and practice, provide a reference for the science and technology enterprises in our city is in transition.
Reporters came to Jiangsu Wanbang pharmaceutical recombinant protein drugs Engineering Center is located in the peach mountain road, Xuzhou economic and Technological Development Zone, the company restructuring nuclear cell drug laboratory, busy school here, chief scientist Dr. Wen Liangzhu and Dr. merry biological products research and development center, R & D is to lead a team of new drugs for treatment of diabetes.
Just a few days ago, Fosun Pharmaceutical announcement, citrate's Jiangsu Wanbang biochemical pharmaceutical Limited by Share Ltd and Chongqing Medical Engineering Institute jointly developed the supporting method for cloth and card farxiga two products, the raw materials and are approved for clinical trials of the State Food and drug administration. Of these, citrate hydrochloride is mainly used for the treatment of moderate or severe active rheumatoid arthritis, and is mainly used to improve glycemic control in adults with type 2 diabetes.
Jiangsu Pharmaceutical Engineering Center, Jiangsu diabetes treatment engineering technology research center, Jiangsu provincial enterprise academician workstation. The company has built the domestic gene prokaryotic and eukaryotic cell engineering class of pharmaceutical R & D and production base, and shared the innovative drug research and development laboratory in the United States of San Francisco, small molecule difficult generic drugs research and development has been in the leading position in the industry. On the basis of strengthening the domestic leading position of hypoglycemic drugs, radiation has developed into the fields of antihypertensive, lipid-lowering and urate reducing products in recent years, and has been extended to the field of anti-tumor therapy.
Prominent innovation carrier platform construction, efforts to increase development potential
Jiangsu Wanbang biochemical pharmaceutical Limited by Share Ltd chairman Wu Yifang introduced the overall R & D company has six major characteristics: sustainable investment, global perspective, international standards, all-round opening up, combining imitation and creation and leaping development. "13th Five-Year" period, the company will continue to increase investment in research and development, focusing on biotech drugs, small molecule drug innovation, high-end generics, international research and development of ANDA and traditional Chinese medicine research fields, the introduction of international advanced technology and team construction, the difference of the R & D center, built into a leading biotechnology drug research and development center, the construction of small molecules with strong competitiveness of innovative drug research and development center, fully integrated into the global innovation ecosystem, construction of the international industrial chain development, to build a global innovation with R & D capability of pharmaceutical enterprises.
In order to strengthen collaborative innovation, Shanghai Institute of Materia Medica, on the one hand and Chinese Wanbang Medicine Academy of Sciences Chongqing Medical Engineering Institute, China Medicine University, Israel, Canada D-Pharma Sirona and other well-known research institutions launched open cooperation, a full range of strategic cooperation between the establishment of new products and core technology; on the other hand, with the domestic well-known institutions launched a long-term clinical trial cooperation on product life cycle.
The company now has independent R & D institutions, R & D sites, construction area of about 13000 square meters. Annual R & D costs accounted for about 5%-8% of sales revenue. Wanbang medicine in the development of new products, other biosimilars will focus on the next step to break through second generation, third generation of recombinant human insulin lispro insulin, insulin glargine, insulin degludec and on microbial fermentation technology, has mastered a number of international advanced core technology.
Up to now, Wan medicine has donated special scholarship to Xuzhou Medical University for 9 consecutive years, the cumulative award of 200 thousand yuan, more than 500 reward students. Set up special scholarships, set up "ten thousand medicine class", support student activities and other public education projects. National pharmaceutical and biological products R & D center and China University of Mining and Technology biochemical direction of experts and scholars, but also established good relations of cooperation.
Wanbang medicine has developed into a comprehensive treatment of the National Diabetes field R & D, production and marketing as one of the leading enterprises, has 65 patents, including 40 invention patents, and grasp the core technology number reached the international advanced level.
